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ABSTRACT
Sanderson, Judy Smith, M.S., July 1981 Microbiology
Recrudescent Herpes Simplex Genitalis: A Clinical Study (83 pp.)
. ,  . -  . IDirector: Marilynn F. Waite - - ' ■ <
A group of 30 women with tentative diagnoses of herpes 
simplex genitalis was studied for six months. The women were 
cultured weekly for herpesvirus from their cervixes, vaginal 
walls and suspect lesions. Serum samples for antibody 
determinations were obtained from the women at various times.
Each woman reported the presence of factors which previous 
workers had suggested might affect recurrent herpes including 
menstrual cycle, sexual activity and subjectively defined 
stresses.
The study determined that five of the women participating in 
the investigation probably lacked herpes simplex genitalis 
infections, despite their previous diagnoses. Another five 
women did not provide sufficient data for analysis.
The information from 20 women was statistically analyzed 
to determine influences on recurrent herpes genitalis. All 
20 women shed herpesvirus asymptomatically during the study.
The only parameter which influenced asymptomatic and recurrent 
herpes in this study was subjective stress. Menstrual cycle, 
sexual activity or birth control methods showed no correlation 
to the disease. Serological data cast doubt on the current 
concept that women with low antibody titers to herpes simplex II 
may be presumed not to have been infected with it.
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Chapter 1 
INTRODUCTION
Herpes genitalis is generally regarded as a sexually transmitted 
disease (36,62), but it can also be transmitted in other ways (35).
It has become of national concern because of its rapidly increasing 
incidence (1A,28,63). It presents a serious problem for several major 
reasons. Subsequent to primary infection the virus becomes latent in 
the host and often causes recurrent disease (51,66). Herpesvirus is 
also proposed to have a relationship to cervical cancer (44,52). 
Additionally, the virus may spread to the fetus before or at the time 
of delivery causing fetal wastage, neonatal disease or death (44). 
Finally, there is no effective treatment to combat the disease ( 5 ,33).
The word "herpes" was derived from the ancient Greek word ëpTiciv 
meaning to creep (35,76). Research on the herpesviruses may be divided 
into three periods (51). The first period (100 A.D. to 1920) uncovered 
the agents responsible for cold sores, shingles and genital blisters. 
From 1920 to I960 animal models evolved to study the extending list 
of diseases caused by herpesviruses. The current period of research 
includes recognition of different biological and epidemiological vari­
ants in the herpesviruses such as herpes simplex types 1 and 2. An­
other important human herpesvirus is varicella-zoster virus, the 
causative agent of both chickenpox (varicella, primary infection) and 
shingles (zoster, recurrent infection).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Herpesvirus 
Molecular Aspects
The herpesviruses are defined on the basis of their structure.
They are large DNA-containing viruses with an icosahedral nucleocapsid 
and a loose outer envelope. Complete viral particles have a diameter 
of 150 nm to 200 nm (51). Centrally located within the capsid of the 
complete virion is a core consisting of viral proteins and the poly­
amine spermine in a,cylindrical structure. The linear, double-stranded 
DNA is wound around this core. The capsid assembles within the nucleus 
of the infected cells; it is composed of 162 structural subunits ar­
ranged to form an icosahedron, 100 nm in diameter. Only core-containing 
capsids become enveloped to form structurally complete, infectious 
virions. The envelope of lipids and glycoproteins is organized into a 
trilaminar unit membrane. It is structurally indistinguishable from 
the cellular nuclear membrane (54).
Variant particles have no or two membranes. Although the single­
envelope particle is probably the epidemiologically important infectious 
unit, infectivity has been reported for the unenveloped particles (34). 
While there are other explanations for these results, they do raise 
questions about the effectiveness of the immune responses which are 
directed against the envelope glycoproteins. The particles with two 
membranes are infectious; several theories have been propounded to 
explain how they might arise (51), but experimental data are lacking.
Relationships Between Herpes Viruses
Herpesvirus DMAs range from 80 to 150 million Daltons and from 
32 to 74 moles percent G + C base composition. Herpes simple* I and II
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have been reported to share about 50 percent of their DNA sequences. 
Although usually distinguishable by cross-neutralization studies, many 
recombinants between herpes simplex I and II exist, leading to a 50 to 
80% rate of cross-reactivity. For epidemiological reasons, it
is sometimes useful to distinguish between the plethora of herpes 
simplex strains. This is usually done by restriction endonuclease 
mapping (65). The genetic relatedness between herpes simplex viruses 
and other human herpesviruses (varicella-zoster, cytomegalo-) is only 
a few percent. However, HSV shares 14 percent of its sequences with 
bovine mammilitis virus and 8 to 10 percent with pseudorabies virus (64).
The herpesvirus genome can code for about 100 virus-specified 
proteins. Of proteins recognized serologically, relatedness between 
the various herpesvirus groups is sparse. Consequently, serological 
methods have no place in the definition of the virus group (76).
Viral Infection— Lytic
Three types of infection exist: lytic, latent and transforming.
Productive lytic herpesvirus infection is initiated when the viral 
envelope glycoprotein attaches to a pre-existing receptor site on the 
membrane of the host cell. There is some dispute as to whether the 
virus enters the cell by viropexis (pinocytosis) or by membrane fusion 
(34). The DNA with attendant nucleocapsid proteins enters the nucleus 
where approximately 50 percent to the DNA is transcribed. In the 
cytoplasm, virus-specific RNA enters into free and membrane-bound 
polyribosomes and directs the synthesis of structural and nonstructural 
proteins. Most of these proteins migrate to the nucleus where they 
aggregate with the replicated DNA to form new nucleocapsids. The
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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inner nuclear membrane of the cell acquires new virus-specified proteins, 
Maturation occurs as the capsids bud through that modified membrane into 
the perinuclear space. Viral particles accumulate there and in the 
endoplasmic reticulum (51). Virions leave the cell by an unknown 
mechanism, but the majority are released after cell death and lysis.
The host cell biology is severly altered during a lytic 
herpes infection. Approximately 3 to 5 hours after viral entry, 
cellular DNA and protein synthesis cease. This metabolic shift coin­
cides with aggregation and margination of chromatin and disaggregation 
of the polyribosomes. Host RNA synthesis is reduced by 70 percent 
and the remainder is improperly processed. Reversal of the transmem­
brane potential from -20 mv to +10 mv allows leakage of cellular 
macromolecules (51). The host plasma membrane displays antigens much 
like those of the viral envelope. Another labile envelope antigen 
which has been reported early in lytic infection is also found in cells 
transformed by herpesviruses. This is thought to be a "transformation 
antigen" similar to those found in adenovirus- and papovavirus-infected 
and transformed cells (51).
In lytic infection, approximately 10^ copies of viral DNA are 
made per cell; of these, only 20 percent are encapsidated; and only 
10^ to 10^ viral particles are infectious (51). Whether this means 
that five percent or less of the nucleocapsids are functional or that 
the majority of the infecting particles are degraded before establish­
ing a productive infection is not known.
Viral Infection— Latent
Latent nonproductive herpes infection occurs when the viral
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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genome is perpetuated while the cell survives. Two types of latency 
have been suggested, which may overlap: a dynamic state where virus
replicates at low levels and a static state with little or no progeny 
release (22). Latency leads to recurrent disease and certain types 
of cancer, as will be discussed further below.
In vitro persistent infections of tissue culture cells have been 
used to study latency. These infections may or may not be valid models 
for iju vivo latency. Such studies include the use of antibodies or 
interferon in the culture medium, or low-temperature incubation of 
virus-infected cells (59). Also, cell lines partially sensitive to 
herpesvirus infection, such as Chinese hamster cells, have been used. 
These cells, when infected with herpesvirus go through cycles of viral 
synthesis and cell destruction, termed recrudescent infection, followed 
by regrowth of the cell cultures (32). During these cycles, progeny 
virus appears to change its level of virulence and the host cell 
population its susceptibility to viral infection ( 32). Recrudescent 
infection can also be seen with Earle’s L cells (59).
For recurrent diseases to manifest themselves, four sources of 
virus may be possible: exogenous infection; endogenous infection from
another site of the body; chronic, continuous low-level viral multipli­
cation around the site of involvement; or persistence of virus in a 
nonreplicating form (51).
Herpes-infected animals can be reinfected with the same strain of 
virus from outside their own body as has been shown by studies in Cebus 
monkeys (43) and observed in man, when partners with HSV reinfect each 
other(6l). Endogenous infection from another source on the body is 
presumed to cause genital herpes in persons with oral HSV and no history
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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of sexual intercourse. This is thought to be the cause of most genital 
herpes infections in celibate populations. One such group is nuns (49), 
Such endogenous infection could occur even in the absence of active 
oral lesions, since HSV has been isolated from lacrimal and oral secre­
tions of persons between recrudescent herpes labialis episodes (23,68). 
The site of replication of this virus, isolated in the absence of 
lesions, is not known. However, because continued efforts to isolate 
virus from the site of lesions between recurrences have failed, chronic- 
continuous infection at the site of the recurrent lesions is unlikely.
For recurrences to occur, previous primary infection by herpes­
viruses, even if asymptomatic, must have existed and have been followed 
by latency. The existence of severe prodromal pain and the effect of 
therapeutic or traumatic severing of nerve roots lead to the hypo­
thesis that after the primary infection, herpes simplex viruses advance 
to the nerve ganglia (20). This is also true in the case of varicella- 
zoster virus as indicated by the location of the recurrent zoster le­
sions. In the nerve ganglia herpesviruses appear to reside in a 
noncytocidal, noninfectious form. In support of this, herpes simplex 
antigens have been detected in at least one malignant glioma (22).
Virus can be isolated from the trigeminal ganglia of human cadavers (Ĝ K) , 
the sacrociatic ganglia of mice after footpad injection of virus, and 
the trigeminal ganglia of rabbits after corneal inoculation (57,69). 
However, all viral isolations from ganglia must be done by nerve 
co-cultivation with susceptible indicator cells ( 10,57,69) or nerve cell 
pre-cultivation ( 8 ). Infectious virus has not been found in nerve
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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cell homogenates (8,10,57,69)- This confirms the inactivity of the 
infection and suggests that some step in the process of nerve tissue 
manipulation stimulates virus progeny production. Herpes simplex 
virus may also be harbored in lymphocytes (41), but the relevance of 
this site of infection to recurrences is unknown.
By some unknown mechanism, stimulation of virus replication in 
latently infected cells occurs, resulting in a recurrence of clinical 
disease. Precipitating factors include trauma and stress, and may 
include sexual activity and/or hormonal changes including those in­
volved with menstruation. Anaphylactic and Arthus reactions in 
rabbits induce recrudescent herpes encephalitis (59). Such nonspeci­
fic reactivation also occurs in man. Organ transplant patients often 
display herpes infections of simplex, zoster or cytomegalovirus 
varieties ( 1,53). Burn patients also exhibit lesions of recurrent 
herpesvirus infections (51). The nature of the stimulatory effect 
upon the site of latent infection is unknown.
Viral Infection— Transforming
All herpesviruses share some biological and physical features. It 
follows that since one herpesvirus (Epstein-Barr virus) has been shown 
to cause cancer in man (38) and other herpesvirus cancers exist in 
animals (Marek's disease in chickens, Lucke renal carcinoma of frogs 
and lymphomas in some primates), that all herpesviruses are suspect 
as cancer-causing agents. In general, tumors (iui vivo) or cell trans­
formation (iui vitro) appear to arise when there is interference with 
lytic replication of virus. In this regard, EB virus may be somewhat 
of an anomaly since the virus can be demonstrated in established cell
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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lines derived from cases of Burkitt's lymphoma. However, the virus 
cannot be isolated from the tumor tissue itself (38), so this anomaly 
may be more apparent than real. Many unanswered questions still remain 
regarding the mechanism of oncogenesis of EB virus, its role in naso­
pharyngeal carcinoma (38), its interaction with malaria (46), and 
its more common role as the etiological agent of infectious mono­
nucleosis .
The relationship between ability of the virus to cause tumors and 
its inability to replicate lytically has been worked out best for the 
naturally temperature-sensitive Lucke frog adenocarcinoma virus (LFAV). 
The LFAV replicates normally at cold temperatures (e.g. in the winter). 
Under permissive conditions virus production, cell lysis and regression 
of pre-existing tumors can be observed. In the summer the higher temp­
eratures restrict the virus replication. Infected cells lack inclusion 
bodies and fail to produce virus, and dramatic tumor growth is found 6 9 ).
Marek's disease, an infectious lymphoma of chickens, was found, 
after extensive studies to be caused by a herpesvirus. At first, 
only a cell-associated agent could be found and no transmissable agent 
was isolated from the lymphoma cells. Later, non-transformed cells 
of the feather follicles were found to shed infectious virus ( 12).
Herpes simplex virus of type 1 and 2 have been shown to cause 
transformation of baby hamster kidney cells in culture, but only 
when the viruses were first inactivated with ultraviolet light (24,39). 
Those viruses have been implicated as causative agents of nasopharyngeal 
and cervical carcinomas (23). The association of HSV II with cervical 
carcinoma is circumstantial but persuasive, and will be discussed more
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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fully below.
Another herpesvirus, herpes saimirl, appears to be involved in 
oncogenesis of some tissues. Isolated from healthy squirrel monkey 
kidneys, it will produce lymphomas in several other mammals in the 
absence of observable intracellular virus replication (21).
Immune Response
In vivo, the host reacts to a herpesvirus infection by two means, 
specific and nonspecific (42). The specific response includes pro­
duction of anti-herpes antibody. Antibody, together with complement 
and activated T lymphocytes, lyse extracellular virus or virus-infected 
cells (which carry viral antigen on their surface) (19). A nonspecific 
immune response is also generated in which inflammatory cells (macro­
phages and lymphocytes) and several mediators (lymphotoxins, interferon, 
etc.) act on infected cells to prevent spread of virus to uninfected 
cells (42).
For a host to be susceptible to a herpesvirus infection appro­
priate conditions must prevail. Substantial inoculum must be intro­
duced before disease will occur. Low viral inocula only induce infec­
tion when the host lacks sufficient antibody from previous exposure or 
is immunologically compromised (as with another disease or immunosup­
pression). Trauma is often involved with herpesvirus infections. Un­
like the situation with many infectious agents, the presence of detect­
able anti-herpes antibodies does not indicate immunity to herpesvirus. 
Persons with serological evidence of exposure to herpes may exhibit 
recurrent infections of endogenous or exogenous origin (61).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Herpes Simplex 
HSV I
Herpes simplex virus type I (HSV I) is acquired by oro-respira- 
tory transmission and is generally considered to cause above-the-waist 
infections (61). It is responsible for about 10 percent of genital 
herpes in women; in these infections there is little involvement of 
the cervix (16). Most people are exposed to HSV I early in life 
(1 to 3 years of age), with 70 to 90 percent of 5-year-olds possessing 
antibodies to it. This varies with socioeconomic class and geographic 
area and is decreasing, especially in the upper classes (61).
HSV II
Most below-the-waist herpes infections are due to HSV II. The 
common HSV II diseases are contracted venereally. Consequently, the 
age of exposure coincides with maximum sexual activity, with 40 to 
70 percent of 20- to 30-year-olds exhibiting HSV II antibody titers (61).
Males with genital herpes generally manifest sores in the penile 
area. The symptoms range from none (one study found that 15 percent 
of males harbor HSV II without a history of the disease (15)) to severe 
illness. Women tend to demonstrate more nonspecific symptoms of 
genital herpes, most frequently vaginal and/or anal burning and itching. 
Lesions, which can be extremely painful, commonly occur in the vagina, 
vulva, cervix or perineum and less frequently on the thighs, buttocks 
or mons pubis. Approximately 40 percent of women have only minor 
discomfort. Forty percent of the serologically positive women have 
no history of lesions (61).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Cervical Cancer
Women with genital herpes have a higher incidence of cervical 
carcinoma than other women (45̂ 49 ). However, the causality of the rela­
tionship is open to debate. The incidence of cervical carcinoma is 
strongly correlated with the onset of sexual activity at an early age 
and a large number of sex partners. One study shows that nuns have 
no incidence of genital herpes or cervical carcinoma ( 4 9 ) .  Thus, 
cervical carcinoma appears to be a venereal disease. The presence of 
cervical cancer is better correlated with the presence of anti-herpes 
simplex II antibodies than with any exposure to other venereal disease 
or with other parameters of sexual behavior (36). Antibody to the 
early antigen of HSV is detectable when a tumor is present, and dis­
appears after removal. Human cervical carcinomas contain RNA trans­
cripts complementary to 5 percent of HSV II DNA. They also contain 
one DNA fragment with 39 percent of the herpesvirus genome per carcin­
oma cell (27). In spite of these observations, HSV involvement with 
cervical cancer remains circumstantial. There are almost certainly 
other causes of cervical carcinoma. ^  vitro the cancer cells are more 
susceptible to viral infection than normal cell cultures. Thus it is 
possible that herpes simplex II virus may be a secondary infection of 
cells newly made cancerous by some other venereally transmitted agent.
The final proof may not occur until vaccines for either HSV II 
or cervical carcinoma are available, and protected vs. unprotected 
groups are studied. However, the risks involved with viral vaccines 
would appear to limit the ability to test a potential vaccine in humans. 
For example, inactivated vaccine would have damaged DNA which could
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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itself possess transforming potential; live vaccine might possess the 
ability to remain latent triggering recrudescent disease; one rendered 
less pathogenic for a test animal such as a monkey might develop 
increased oncogenic potential for humans in a manner analogous to 
herpes saimiri; a non-replicating variant might have increased onco­
genicity like the Lucke frog adenocarcinoma virus (33, 78 ). Also, 
the failure of the immune response to prevent recurrences and reinfec­
tions could prevent the development of an effective vaccine against 
HSV II.
Infant Disease
Neonatal herpes is usually contracted when the fetus passes through 
the birth canal of an infected mother (with or without symptoms) (5 0 ).
If virus is known to be present at birth, precautions such as Caesarian 
section decrease the chances of infection. Caesarian section is 
only useful if performed within 4 to 6 hours after the membranes 
rupture. Greater time allows migration of virus to the fetus (37).
An estimated 50 percent of babies exposed to HSV at birth contract it.
Of those, 50 percent die. The remainder exhibit symptoms of neonatal 
herpes which appear within the first four weeks of life and vary from 
"nonspecific failure to thrive" to severe lifelong sequelae. Recent 
studies indicate that infants who possess substantial maternal antibody 
titers to herpesvirus present less severe forms of neonatal disease 
than infants with little or no maternal antibody. Thus, antibody 
levels also influence the eventual outcome of the infection (79).
Babies from mothers with high antibody titers show less severe sequelae 
than those from mothers with no antibodies. In the future, monitoring
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the mother's antibody level in conjunction with viral cultures may 
help physicians determine which women are candidates for Caesarian 
section (37).
Diagnoses of HSV
Herpes genitalis is a reportable disease in only two states—  
Arizona and Georgia. Herpes genitalis is generally diagnosed by 
intensive histories of patient symptoms rather than by virus 
identification. Some physicians and clinics choose to confirm their 
diagnoses through use of microbiological methods. Several available 
tests include direct observation, serology and culture (11).
Direct observation is done by scanning a Papanicolaou smear for 
giant cells with nuclear inclusions, or by observation of smears 
treated with dye conjugated to anti-HSV antibodies. To diagnose 
genital lesions the VDRL test has been used to screen out syphilis. 
VDRL-negative patients may then be tested for herpes antibodies (CF 
(11), SN (48), IHA (58) or, most recently, ELISA (74)}. The state 
of Montana regards persons with IHA antibody titers of <1:8 as negative 
for HSV. Serology should include acute and convalescent sera to 
detect a rise in antibody level. The above tests are susceptible to 
misinterpretation because neither giant cells nor nuclear inclusions 
are limited to HSV. Antibody-dye techniques and other serological 
assays can yield false negative results. The reasons for this are 
unknown. Only the paired serum methods are indicative of recent 
inf ection.
To culture for HSV, a swabbed sample from the infected or suspect
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area is inoculated into a small amount of transport medium containing 
nutrients to stabilize the virus and antimicrobials to reduce overgrowth 
by bacteria or fungi. This transport medium, with or without filtration, 
is subsequently added to cell cultures which are used as indicators of 
infection (71). Herpesvirus infection induces a typical cytopathic 
effect in certain cells which is diagnostic (73). Further confirmation 
can be done with the aid of specific antiserum.
Treatment
Countless attempts have been made to find a cure for herpes geni­
talis. Topical ether was supposed to destroy the viral envelope, ren­
dering the virus noninfective (5 ). The solvent properties of the ether 
actually irritated lesions so that healing was delayed ( 18,30), and it 
did not kill all the infecting virus. Another formerly popular treat­
ment was a dye-light treatment ( 5). The dye was applied to denuded 
ulcers of herpes, followed by exposure of the area to a specific 
wave length of light. The heterocyclic dye intercalated into the viral 
DMA and broke it when exposed to the light (39). Several studies 
yielded conflicting results on the efficacy of this procedure (39,47), 
and the possibility that damaging the viral DNA could increase the 
risk of cancer has caused this treatment to fall into disfavor (39,47).
An attempt to treat herpes genitalis with 2-deoxy-D-glucose 
yielded an 89 percent cure in a two-year study of 36 women. This 
compound was first introduced in 1959 as a treatment for influenza. It 
inhibits glycosylation of glycoproteins and glycolipids so that the 
complex carbohydrate sidechains normally found in these molecules are 
not formed; precursor molecules accumulate, preventing envelope formation,
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It appears that 2-deoxy-D-glucose can prevent UV inactivated HSV from 
transforming primary hamster cells { 13).
Immunological boosters have been studied for their effect on 
recurrent herpes genitalis. Vaccines such as smallpox, polio and 
BCG ( 5) appear to mhance cellular immunity, limiting recurrences 
and/or the length of attacks. The danger of encephalitis from the 
smallpox vaccine has limited its use. BCG still appears promising ( 6 )• 
Of all the treatment attempts, nothing works as consistently 
for limiting the symptoms as a drying agent to speed lesions healing 
along with antibiotics for secondary infection of the lesions (5 ).
For life-threatening herpes infections, nucleotide analogues are 
employed, lododeoxyuridine, cytosine arabinoside and adenine ara- 
binoside (Vidarabine) do stop raging systemic herpes infections.
Often times the virus has done considerable damage before the drug is 
used; and, the drugs also affect rapidly growing cells { 5, 7 ). 
Consequently, the cure is not without dangers and an accurate diagnosis, 
which often requires a brain biopsy, is essential before instituting 
treatment ( 9). Trials with topical nucleotide analogue treatment
for genital herpes have been inconclusive ( 4).
Statement of Thesis
This study was designed to investigate the occurrence of lesions 
and genital virus shedding by women with a history of recurrent herpes 
genitalis over an extended period of time. The University of Montana 
Student Health Service and local physicians regarded this study as a 
diagnostic aid. Based on the criteria available at the time, approx­
imately one-sixth of the women in the study had no evidence of previous
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herpes infection. However, some evidence acquired in this study 
casts doubt on these criteria.
Specific aspects of the virus studies included: 1) time since
primary infection; 2 ) success of viral cultures obtained from active 
lesions; 3 ) source of virus shedding (cervix, vagina and/or lesion);
4) frequency of symptomatic or asymptomatic virus shedding; 5 ) ser­
ological data; and 6 ) effect of factors which have been reported as 
related to recurrent disease or virus shedding such as a) menstrual 
cycle, b) sexual activity, c) method of birth control, d) emotional 
or physical stress.
The original goal of the study was to attempt to discover patterns 
of virus shedding and/or lesion occurrence either for the entire group 
or for the individual participants. When the data did not reveal 
immediately obvious trends, they were filed for 2§ years. Systematic 
réévaluation of the results revealed previously unperceived patterns 
and correlations. Computer analysis of the data, a follow-up inter­
view and serological assays were conducted to conclude the study.
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Chapter 2 
MATERIALS AND METHODS
Subjects
Initial
Female volunteers were obtained with assistance from the 
University of Montana Student Health Service physicians and several 
Missoula gynecologists. Some of the original 30 patients were diag­
nosed as having herpes genitalis without serological or culture con­
firmation. Previous to 1977, our lab performed all diagnostic confir­
mation of herpes for free. When a charge was instituted, some phy­
sicians ordered cultures only in atypical or high risk cases. Some 
patients were referred to the study as a diagnostic aid by second 
physicians who doubted previous diagnoses. The following handout
was distributed by the physicians (Exhibit A). An ad was also run
in the university newspaper the Kaimin.
The potential subjects were screened in December 1977 using the
following interview form: (Exhibit B).
Those persons who agreed to participate in the study were supplied 
with the following daily log sheets upon which specific possible 
contributory factors were recorded by the person. No pressure was 
given to provide data. (Exhibit C)
Upon completion of the study, persons keeping fewer than seven 
appointments-and/or withholding the daily log sheets, or clearly lack­
ing a genital herpes infection (determined serologically and/or with 
an in-depth discussion) were eliminated from statistical analysis
(10 of 30 persons; see Table 1). For the most part, the dependable
17
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18Exhibit A
HERPESVIRUS TYPE II: YOU ARE INFECTED FOR LIFE!!
The incidence of Herpesvirus hominis type II (Herpes simplex) 
infection is increasing at an alarming rate. There are many reasons 
for this epidemic, but we will not discuss them at this time. Al­
though the virus is transmitted most commonly through sexual inter­
course, the disease can be contracted by other means. A particular 
concern is for the newborn who contracts the infection from the 
birth canal. Unlike the gonorrhea or syphilis microorganism, herpes­
virus is much more stable, and the infection cannot be controlled 
by antibiotics. In fact the infection lasts a lifetime, and the 
individual will shed the virus at variable intervals.
Lesions (sores) do not necessarily accompany the shedding.
For that matter only a small percent of those infected are aware 
of having contracted the virus and only because these individuals 
develop the sores or give birth to infants who soon show the clinical 
signs of the infection. In one of our studies conducted in Missoula, 
we found that in one large group of pregnant women without any pre­
vious history of vaginal lesions, 10% of the women were shedding 
the virus during the eighth month of pregnancy.
We are very interested in learning the frequency that an indivi­
dual will shed the virus. By taking weekly swab samples from the 
vaginal wall and the cervix for several months, we will be able to 
prepare a profile correlating many variables (e.g., menstrual cycle, 
sexual frequencies, stresses of many kinds, etc.) with virus pro­
duction. If you are interested in knowing your shedding frequency 
and wish to participate in this study, your cooperation would require 
weekly visits to the health service and the maintenance of an accurate 
record noting the factors that could trigger virus synthesis. A 
trained person will take the swab samples. If you are willing,
2 mis of your blood taken once a month would be used to monitor your 
immune response. All records will be kept confidential.
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Exhibit
Recurrent herpes: Patient interview
B
Patient's name: Date :
Physician : Birthdate:
Interviewer: 
Home town : Local address:
Age : Sex : Race:
Marital status: Year in school :
1. History of recurrent herpes infection:
A. type: genitalis , labialis , gingivo-stomatitis
B.
C.
First known occurrence of present 
Duration of l" attack:
condition: 
treatment :
D. Frequency of subsequent attacks: any pattern:
E. Average duration of 2® attacks: treatment :
F. Site of lesions: does this vary:
G. No. of lesions: does this vary:
H. Size of lesions: does this vary:
1 . Are attacks elicited by any apparent trauma, event, food, etc.:
how long after such trauma, etc.:
J. History of any other herpetic type lesions (varicella-zoster):
II,
A.
Medication history: 
any medications taken on a regular basis:
1. oral contraceptive (brand):___________
asp i r i n ______________________
how long:
2.
3.
4.
5.
6. 
7. 
8
hormones (what)
antihistimines (what):
cortisone ;___________ _
digitalis: _____
antibiotics (what) 
other:
B. Any changes in medication that resulted in changes in the pattern 
of your recurrent herpes :___________________________________________
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(Exhibit B continued)
III. Sexual practices:
A. Age of first sexual activity:
B. Frequency of sexual relations:
C. Type: Genital__________Oral  , Rectal
D. Total number of partners:
E. Number of partners with whom you are presently having sexual 
relations :__________________________________________________________
F. Have any of your partners suffered genital and/or oral herpetic
type lesions either before or after contact with you:___________
at the time of sexual contact:
G. present contraception method employed: 
for how long: _________________
H. Do you see any relationship between any changes in contraception 
methods and your recurrent infection:
Have you ever had any other venereal disease: 
when: Rx:
J . Have you ever been pregnant :_______________  when :
K. Outcome of pregnancy : ____________
L. Any change in the pattern of your recurrent infection during
pregnancy :_______________________________________________________
IV. Notes and Comments:
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Exhibit C 
DAILY CALENDAR
21
Record several criteria which could influence the herpes shed­
ding (some of which are listed below). Please turn in the previous 
month's record on your first visit to the health service each month.
Calendar .information;
e.g. WEDNESDAY
1 1 11 111 IV
V VI
1
II
III 
IV
menstrual cycle— record day 1 as the first day of flow
birth control pills (what kind?)— start with 1 for each month
sexual activity— indicate different partners if applicable
lesions— record a + during each day noticed, also note location 
and number
stress physical 
F— fatigue
1— general infection, especially with a fever
V— vaginal infection (other than herpes) 
o
VI
— (fever— record) 
environmental
H— extreme heat or rigorous exercise 
E--exam
0— some other tension causing event 
culture— vaginal and cervical (we will add)
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participants in the ordeal (7 to 17 appointments) were extremely 
helpful and enthusiastic about their role in contributing to the 
future knowledge of herpes genitalis.
Follow-up
In April 1981 a three-year follow-up study of the 1978 genital 
herpes group was initiated. The following letter was sent to 13 
persons whose addresses were found:
Dear _______:
I am carrying out a follow-up on the 1978 study at the 
University of Montana Student Health Service of which 
you were a part. If you are willing to participate in 
a follow-up interview, please contact me at the above 
address or phone number. I appreciate any further 
assistance that you can give me. Thank you.
None of the letters were returned by the Postal Service, suggesting
that they all reached their destinations. Seven of the 13 persons
responded affirmatively. They were sent the following form: (Exhibit
D). Three persons were sent an additional note:
Dear ______ :
Since I work in the medical field, I overlooked the 
possibility that having blood drawn could cost a sum 
of money. Please excuse this thoughtlessness. Feel 
free to send me the bill; or, call me collect— I may be
able to make arrangements by phone for someone to draw
the sample for nothing. Thanks again for your help.
I hope to hear from you soon.
One reply included "... It only cost a small donation and a bruised
and sore vein..... No need to reimburse me— I am glad to be a part
of the study..."
Due to circumstances beyond control, the serological study included 
in the follow-up was not completed for this manuscript.
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Exhibit D
Dear_______:
Please answer the following questions as completely as possible and 
return this questionaire with the enclosed self-addressed mailer.
Thank you, again.
1) Did the study change your attitude about your herpesvirus infection?
2) Did it make you more aware of (your) herpesvirus?
3) How many outbreaks have you had since June 1978? 
(approximate if you don't know the exact number)
4) How frequent are the recurrences now?
5) Do you have a pattern of recurrent infections? 
(can they be predicted?)
6 ) Has the pattern changed? 
(elaborate)
I have included a 5cc tube and mailer. I am extremely interested in 
a follow-up serological study of the persons in the 1978 study. If 
you could get a friend or clinic to draw a small amount of blood for 
serum, and remove the serum into the tube provided here, and return 
it with the questionaire I would be most grateful. I will alert you 
to any publications that arise from the study.
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Culturing 
Sampling Technique
Medium disposable plastic specula (Sani-Spec, Burnett Inst. Co., 
Lawrence, Kansas) were reused for each participant in the study 
(numbered upon first use). One subject required a smaller size; 
a small stainless steel instrument was borrowed from the Student 
Health Service for each visit. These specula were steam sterilized 
between uses and stored in clean drawers used only for that purpose 
at the health service.
Each visit conducted at the health service consisted of an 
external exam for lesions or other infections, followed by insertion 
of the speculum. (Several of the first-week exams were performed 
by the health service nurse practitioner for demonstration purposes.) 
Separate samples were obtained from the cervix, the vaginal walls 
and lesions if present, using sterile wooden-shafted cotton swabs.
Each swab was placed in a separate transport tube containing medium 
(see appendix), and was stored at for 5 h or less before ino­
culation onto cell cultures.
Indicator Cell Cultures
African Green Monkey Kidney (VERO) cells (initially obtained 
from Donald Lodmeil, Ph.D., RML) were utilized for virus growth studies 
The cells (in 75 cm^ Corning tissue culture flasks) were passaged 
weekly (split ration 1 to 3 ) using a standard trypsinization pro­
cedure. Medium was removed by aspiration and the cell layer washed
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with Pd(appendix) containing 1% glucose. Trypsin (DifCo) solution 
(0.15% plus versene) was added (1.0 ml per flask). Cells were in­
cubated with trypsin solution at 37°C for up to 15 min. Following 
detachment of the cells, 5 to 10 mis of medium with 10% FCS were 
added to the flasks to terminate the enzyme action. Vigorous pipet­
ting fur'ther dispersed the cells. Suspended cells were removed to 
a 15 ml conical centrifuge tube and centrifuged at 700 to 1000 rpm 
for 5 to 10 min. The supernatant fluid was aspirated, and the cell 
pellet was resuspended in the desired volume of medium by forceful 
trituration.
One day before testing samples for herpesvirus, glass tubes 
(GIBCo) were seeded with 1 ml of MEM + 5% FCS containing 1 to 5X10^ 
VERO cells. A sterile Cornwall syringe was employed to dispense 
the cell suspension. The cultures were incubated at 37°C for 18 to 
24 h. Other cell lines used in tandem with VERO cultures included 
HEp-2 (weeks 5,6 and 7) and primary rabbit kidney (week 11), both 
obtained from Rocky Mountain Laboratory. In no case did either 
of these cell types exhibit a herpes CPE when the VERO cells did 
not; in fact, the VERO cells were more sensitive to herpes than 
either HEp-2 or rabbit kidney cells, and the use of the alternate 
cells was abandoned.
Virus Assay
Patient samples were inoculated onto cells within five hours 
after they were obtained. The first four weeks, one VERO cell tube 
was used per sample. Subsequently, each sample was cultured in 
duplicate either in one VERO cell culture and one other cell type
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or in duplicate VERO tubes. In only 40 cases (6% of the total number 
of cultures) was virus growth obtained in one tube but not in the other. 
After inoculation the volume of medium in each tube was brought to 
approximately 2 ml. The tubes were incubated at 37°C in a roller drum 
so as to avoid possible loss of a culture due to a skewed tube. Each 
tube was observed daily on a tube holder (GIBCo) with an inverted 
microscope (American Optical) for cytopathic effect of the cell layer 
due to herpesvirus infection. The results were observed as 1+ for 
25% involvement of the monolayer to 4+ for 100% affected cells. Cyto- 
pathology consisted of rounded, balooning cells which originated in 
"foci" in the monlayer and spread to involve the entire culture.
(Since all 1+ cultures eventually became 4+, results are recorded as 
+ and - only.)
One isolate from each patient was centrifuged at lOOO rpm for 
10 min and the supernatant fluid passed to a new indicator tube. All 
such isolates showed CPE on serial passage, indicating that they were 
herpes simplex infections. Varicella-zoster, the herpesvirus which 
causes chickenpox and shingles would not have caused cytopathology 
upon subcultivation since it is a cell-associated virus (20 ) • The 
isolates could not have been cytomegalovirus because those CPE do 
not appear for 10 to 21 days (73) and not in the cell lines used in 
this study. Neither could they be Epstein-Barr virus because EB virus 
cannot be grown in normal cells (38 ) •
To further confirm that the CPE was that of herpes simplex virus, 
isolates from three patients (F, I and R) were tested by serum neutral­
ization using known antisera prepared in guinea pigs. All three
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isolatewere neutralized by a 1:64 titered anti-herpes simplex II 
serum, confirming that the isolates were herpes simplex virus.
Freezing Cells
Seed cultures were stored at -70°C (REVCO) and -192°C (liquid 
nitrogen refrigerator— Linde) in 1 ml quantities at a concentration 
of 5X10® cells/ml. Dimethyl sulfoxide (DMSO—  Mallinckrodt) was added 
to the medium as a cryoprotective agent to a concentration of 10% 
(v:v). The cells were slow-frozen by placing the vials on aluminum 
canes (Minnesota Valley Engineering) and submerging the canes in a 
95% ethyl alcohol-filled cylinder. The cylinder was placed at -70 
for 2 to 4 h after which some canes were transferred immediately to 
the liquid nitrogen storage container. Other vials were removed from 
the canes and boxed in the REVCO.
Thawing Procedure
To revitalize the frozen cells, a vial either from -70®C or 
-192°C was quick-thawed in a 37°C water bath. The cells were centri­
fuged from the DMSO-containing medium and resuspended in 20 ml of 
medium containing 10 to 20% FCS in a 75 cm^ flask. The flask was 
gassed for 10 s with a 5% 00^-95% air mixture, closed and incubated 
at 37°C.
Serum Antibody Levels
Serum samples were drawn by the Student Health Service lab 
personnel, once a month, or as often as the subjects were willing 
(at least once during the study). They were stored at -20®C and heat 
inactivated at 56°C for 1 h just prior to the assay.
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Serum Neutralization
Flat-bottomed, sterile microtiter plates (#3040— Falcon, with 
appropriate lid) consisting of 8 rows of 12 wells each were used 
(total of 96 wells/plate). With sterile, disposable, calibrated 
pipettes (Cooke Laboratory Products), 0.05 ml of MEM with 10% FCS 
was added to wells 2 through 11 of each row, and 0.1 ml to wells 
1 and 12. Then 0.05 ml of the test serum sample(s) was added to 
wells 1 and 2 in every row. Using 0.05 ml microdiluters (Cooke; 
sterilized with 70% alcohol), serial two-fold dilutions of the test 
sera were made from well 2 through 10. The drop remaining in the 
microdiluted was discarded. Well 1 of each row was the serum control 
to determine if the patient’s serum was cytotoxic to the cells. 
Duplicate plates of the samples were set up to test for antibodies 
to HSV I and HSV II.
The virus pools previously titered by the TCID^^method (described 
later) were, diluted to a stock concentration of 100 TCID^^/O.OS ml. 
Then 0.05 ml of the appropriate virus was added to wells 2 through 10. 
Virus titration (described later) was carried out in the wells in 
column 11. Well 12 of each row received neither virus nor serum and 
served as the control to illustrate how normal cells should appear.
The plates were covered and incubated at room temperature (22°) for 
1 h.
During this hour, VERO (indicator) cells were prepared. A 75 cm^ 
flask of cells was trypisinized and the cells were suspended at a 
concentration of 2X10^ cells/ml. Fifty microliters of that suspension 
were added to each well on all plates (1X10** cells/well). The plates
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were incubated at 37°C in a sealed box flushed with 5% COg-95% air.
The plates usually were read in two days (see virus titration).
To determine the neutralization index, the highest dilution that 
inhibited the cytopathic effect was considered the neutralizing titer. 
The wells were read + or - for viral CPE.
Viral Pools
Flasks (75 cm^) of VERO cells were infected with HSV I (Kos strain) 
or HSV II (strain 196; both obtained from Donald Lodmeil, Ph.D., RML). 
When 80 to 100% of the cells were rounded the flasks were freeze- 
thawed twice to release maximum virus from the cells. The suspension 
was centrifuged at 2500 rpm for 15 min to remove the cellular debris. 
The pool was frozen in one-use vials in the REVCO (-70°C) for later 
use.
TCID^o
Determination of the virus titers was performed as follows.
A tube from each virus pool was thawed. Ten-fold serial dilutions 
were made of each stock vifus (10 for HSV I, 7 for HSV II). A 3040 
plate previously seeded with VERO cells was used for each virus. A 
0.05 ml aliquot of the undiluted stock virus or the appropriate 
virus dilution was added to the first 11 wells of each row. Row 
12 received only diluent and remained as uninfected cell control.
The plates were incubated at 37®C in the CO^ box previously described. 
They were read (+ or -) at 48 h . The 50% endpoint was calculated 
by the method of Reed and Muench (40).
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Virus Titration (during serum neutralization test)
To confirm that approximately 100 TCID^^ were used per well in 
the serum neutralization test, a virus titration was performed in 
parallel with each test. Three serial 10-fold dilutions were made 
and inoculated into a like number of wells in column 11. The actual 
titer of the inoculum was calculated by the method of Reed and Muench 
and was 50 to 200 TCID^^ (considered accurate to within one dilution).
Statistical Analyses
The data from Table 3 of the Results section were entered into 
a DEC-20 computer system at the University of Montana in SPSS program 
format by Daryl Paulson, M.S. The data were not normally distributed, 
therefore non-parametric techniques were used. Among the techniques 
he applied to this study are: multiple regression analysis with up
to 13 variables with partial, multiple partial and residual analyses; 
analysis of variance; analysis of covariance; other non-parametric 
statistical procedures; and procedures involving binomial and Poisson 
distributions 05,55,57 ). Most of the tests revealed no statisti­
cally significant differences between groups and no correlations 
between lesions, positive cultures and occurences postulated by other 
workers to be precipitating factors. The statistical analyses up­
held the conclusions drawn from Inspection of the data. Thus most 
of the analyses were not discussed.
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RESULTS
Eliminated Group
From the onset of the study, the diagnosis of herpes genitalis in 
several patients was in doubt because it was made without viral culture 
or serological confirmation. Ten of the original 30 candidates for the 
study were eliminated; half of those apparently did not have herpes 
simplex genital infection. Thus the study allowed five women who 
thought they had genital herpes to be reassured that this was not 
the case. Although four of the remaining five clearly had genital 
herpes simplex infections, they did not participate in the study 
long enough- to allow the accumulation of adequate data. (Table 1)
Study Group
Biographical information about the remaining women who partici­
pated in this study are found in Table 2. A compilation of culture 
results and specific factors affecting herpes recurrences or asympto­
matic shedding can be seen in Table 3. Various parameters will be 
dealt with separately below.
Time Since Primary Infection
Table 4 shows the study group in ascending order for length of 
time since primary herpes genitalis infection. One-half of the group 
had been infected for less than one year. The other half ranged from 
17 mo to over 5 y . The four participants who manifested lesions most 
frequently during the study were in the "short infection" group (S, C,
L and G). However, three of four participants who had no lesions
32
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Table 1
Persons eliminated from study.
age marital 
(1978) status (1978)
25
22
single
single
date herpes 
diagnosed
11/77
11/77
SN titer 
HSVI/HSVII
4/0,2/2 
<4/4
outcome of 
cultures
negative
# of 
exams
no virus 8
yeast contamination
probable diagnosis 
condyloma acuminata
Candidiasis
c 24 single 5/77 0/0,2/<2 1+ from cervix, 
not tested for 
zoster
5 genital zoster
d 18 single 11/77 8/4 negative 4 nongenital zoster
e 28 married a - negative 1 no infection
2 f 
insuff­
23 single 1/76 64/>128 1+ from lesion 5 genital HSV
icient g 
data
22 single B 16/64 negative 5 insufficient partici 
pation
h 25 single 11/76 64/128 2+ isolates 4 genital HSV
î 30 married 4/77 >64/8 1+ from lesion 2 genital HSV I
j
a-
6“
Y-
6-
21 single 1/77
-never diagnosed; husband affected 
-never diagnosed; exposed twice 
-initial diagnosis by virus culture 
-virus isolated at same time
32/128^ 1+ from vagina 1 genital HSV
U)w
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Table 2:
patient
A
B
C
D
E
F
G
H
I
J
K
L
M
N
0
P
Q
R
S
T
age marital
1978) status (1978)
27 single
25 married
23 single
20 single
25 married
20 single
24 single
26 single
26 single
28 married
28 single
28 single
21 single
29 single
25 married
25 single
31 single
22 single
18 single
22 single
number of 
pregnancies
1
1
1
0
1
1
1
0
0
0
0
0
0
0
2
1
0
0
0
0
when
1971"
1977'
1978^
1975
1976
1974m
1969
1971
1970^
icinduced abortion 
l=live birth 
m=miscarriage
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age of first 
intercourse
# of sex 
total
partners
1978
time since 
HSV onset other diseases
21 10 1 1 mo none
19 10 1 24 none
16 >1 1 5 none
19 1 1 17 none
16 ? 1 52 none
15 15 1 37 none
21 1 1 9 none
16 ? 1 64 yeast
21 6 1 40 none
17 <10 1 28 none
20 23 varies 2 none
19 1 1 6 none
17 1 1 4 none
20 5 2 30 none
15 2 1 6 none
17 5 1 3 none
19 unknown 1 35 gonorrhea 2X
22 1 1 1 yeast & Haemophilis
16 4 1 1° yeast & warts
16 >2 0 40 gonorrhea
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Table 3
Culture Results and Affecting Factors 
{Legend)
(patient)
1 pregnant
2 no sexual activity
3 BCG
a after study
b before study
4 primary infection
(culture results)
0 negative culture
c positive isolate from cervix
V positive isolate from vagina
1 positive isolate from lesion
e positive isolate from eye
a absent
b break (Spring)
(affecting factors)
m menstrual bleeding
s sexual activity
t t1 illness
t2 trauma
t3 emotional stress
t4 exam
t5 exercise, overheated
@ serum drawn for antibody titers 
(see Table 15)
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Table 4
Effect of time since primary infection upon frequency of lesions, 
duration of lesions, frequency of viral isolation and antibody titers.
41
number of months it of lesions sum lesion lenrtth It isolates hightient age since 1® infection days in study number of lesions attempts SN
S 18 * 3/126 26t/3 8/16 64/32
A 27 1 1/70 2/1 1/8 32/16
R 22 1 0/140 — 4/15 16/64
K 28 2 1/63 2/1 4/9 4/4
P 25 3 0/126 — 3/12 32/16
M 21 4 0/112 - 6/9 <8/16
C 23 5 4/140 21/4 5/13 32/16
L 28 6 8/133 18/8 6/17 16/2
0 25 6 1/112 6/1 7/14 32/16
G 24 9 3/140 8/3 7/17 8/8
D 20 17 2/140 9/2 4/17 16/32
B 25 24 1/133 17/1 3/15 8/16
J 28 28 1/140 4/1 8/16 16/128
M 29 30 2/119 4/2 11/17 64/<4
Q 31 35 1/126 4/1 4/7 16/64
F 20 37 0/63 — 3/9 512/256
I 26 40 2/140 10/2 5/16 16/32
T 22 40 2/119 3/2 8/l6 64/128
E 25 52 1/133 1/1 5/15 256/128
H 26 64 1/63 4/1 4/9 32/8
■ entered study during 1® attack
t 1“ lasted 22 days
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during the study were also in that group (R, P and M). No differ­
ence was seen between the length of lesions or the number of positive 
cultures for those persons recently infected and those infected for 
a considerable length of time (x length of lesion 4.1 d vs. 4.3 d,
X percent positive cultures 39 vs. 41).
Viral Isolation
Whether lesions were present or not, attempts were made to cul­
ture virus from the cervix and from the vagina each time the patient 
was examined. Whenever a lesion was apparent, it was swabbed directly 
and an attempt was made to culture virus. Successful culture of 
virus directly from lesions was possible 5 of 22 times (22.7% ; see 
Table 5). Lesions were found at a variety of locations listed in 
Table 6. One patient (T) experienced optic neuralgia. A culture 
from her lacrimal secretions yielded herpesvirus. (See Table 7 for 
source of positive cultures.) Only 5, or 3.1% of the positive cultures 
came from lesions. The cervical isolates (84 or 52.2% of the total) 
were slightly more numerous than vaginal isolates (72 or 44.7% of the 
total). Two participants had positive viral isolates from the cervix 
more than twice as often as from the vagina (I and K). They did not 
have cervical lesions during the study.
Asymptomatic Shedding
Of 268 culture sets (cervical, vaginal, plus any suspect lesion), 
106 cultures were positive for herpesvirus (39.6%). The 39.6% were 
further divided into those that could be related to lesions (+1 wk) 
and those that involved asymptomatic shedding. In this study, 74.5%
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table 5
Isolation of virus from lesions
patient with lesion culture negative culture positive 
on culture day (failure) (success)
B 2/3 1/3
C 4/4 0/4
D 1/1 0/1
E 1/1 0/1
G 1/1 0/1
H 0/1 1/1
I 1/1 0/1
J 0/1 1/1
K 1/1 0/1
L 3/3 0/3
M 1/1 0/1
Q 0/1 1/1
S* 2/3 1/3
total 17/22=77.3% 5/22=22.7%
* 1° lesion included
Table 6
Location of lesions
A slightly forward of clitoris^
B left side of vulva and anal
C left side of vaginal opening
D vaginal
E perineum
G (did not specify)
H left side of labia
I perineum
J left labia
K inside base of vulva
L vaginal
N lower outer vulva
0 pubic area
Q right lip of vulva
S around anus
T inside vaginal opening
a
6 unable to cultureone attack may have been exogenous reinfection 
(manifest at a new site which was not specified)
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Table 7
44
Area from which positive cultures were obtained every week from 
person (week 10 was Spring Break— no examinations).
each
week total
.ient 1 2 3 4 5 6 7 8 9 n 12 13 14 15 16 1718 19 20 C V 1
A o o o o V a 0 o o 1 0 0
B a o cv o o 0 o cvl 0 a o V o o o o a o 2 3 1
C o a 0 o o cv V cv o a a a a a o o cv 6 V 3 5 0
D o o o o a c o cv o cv o o o o o o a CV 0 4 3 0
E 0 o 0 V o 0 a cv cv a o cv o a a o o o c 4 4 0
F o o o o c 0 o cv cv 3 2 0
C o 0 a o o c o cv v v o V c a 0 o c o 4 4 0
H 0 o o c o c cvl cv o 4 2 1
I o o o c o o cv c a o o c o o o o a a c 5 1 0
J o 0 a c a a cv o o cv c cvl CV 0 o o cv cv o 8 6 1
K 0 o o o c c c o c 4 0 0
L a o V o V c o o cv o V c o o o o o o 3 4 0
M cv o o a cv a cv cv o a cv CV 6 6 0
N 0 c 0 cv V cv c cv o c c o c o c V o 9 5 0
0 o o o cv cv o 0 cv o V CV 0 V c a 5 6 0
P 0 o o c 0 a cv V a o o o a a a o o 2 2 0
Q o c o o a cvl cv cv a a a a a a a a a 4 3 1
R a a o o 0 o cv V o o o o cv V o o a o o 2 4 0
S a 1 o 0 cv cv o o o CV o c cv 0 cv V o 6 6 1
T V 6 V cv v o cv cve o o o o o o c c 5 6 0
84 72 5
52,2% 44,7% 3.1%
blank:not in study at that time
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of the positive isolates had no relationship to noticeable lesions.
In all but two cases (C andL) the majority of positive cultures were 
obtained in the absence of lesion. Also note that all participants 
shed virus asymptomatically. (See Table 8.)
Although only 25.5% of the viral isolates were obtained during 
recurrences of lesions, only 10.8% of the attempts to isolate viruses 
were made during these recurrences. The remaining 89.2% of the attempts, 
made in the absence of lesions, led to 74.5% of the virus isolations.
Thus it would appear that the likelihood of isolating virus during a 
recurrence is more than 2.8 times greater than it would be from an 
asymptomatic patient. The McNemar related sample test (non-parametric) 
gave a confidence limit between .85 and .90, which may be significant 
considering the small sample size.
Factors Which Might Affect Recurrences of Lesions and/or Viral Shedding 
Menstrual Cycle
For purposes of this study, menstruation was analyzed in two ways. 
Menstrual bleeding or "menses" began on day 1 of bleeding and included 
all days of bleeding. Of the time period covered by this study, 15.8% 
of it occurred during menses, with 20% of the lesions and 13.9% of the 
positive viral cultures. (See Table 9a.)
The menstrual phase was defined as two days before bleeding and 
all days of menses, to include the post-secretory phase. (This is 
2 days longer than denoted by "m" on Table 3.) The menstrual phase 
included 22.6% of the study period, 34.6% of lesions and only 17.8% of 
positive cultures. Because of scatter of the sample group, these
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 8 4 6
Relationship of positive cultures 
to the presence (± one week) of■detectable lesions 
(asymptomatic positive cultures)
patient positive* cultures 
times cultured
positive cultures 
in absence of 
lesions (± 1 wk)
{% of positive cultures)
A 1/8 1 ( 100)
B 3/1 5 2 (66.7)
C 5/13 2 (40)
D 4/17 3 (75)
E 5/15 4 (80)
F 3/9 3 (100)
G 7/17 6 (83.3)
H 4/9 2 (50)
I 5/16 4 (80)
J 8/16 6 (75)
K 4/9 3 (75)
L 6/17 1 (16.7)
M 6/9 6 ( 100)
N 11/17 10 (90.9)
0 7/14 6 (83.3)
P 3/12 3 (100)
Q 4/7 2 (50)
R 4/16 4 (100)
S 8/16 6 (75)
T 8/16 (62.5)
total 106/268=39.6% 79 (74.5)
*positive culture from any site tested
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Table 9a
The relationship of menstrual bleeding to lesions and/or viral shedding.
days of bleeding lesions in menses + cultures in menses 
patient total d in study total lesions total positive cultures
lesions and+ cultures in menses 
total lesions and positive cultures
8
33"
CD
CD■DOQ.Ca
o3"O
o
CDQ.
■DCD
C/)C/)
A
D
E
F
G
H
I
J
K
L
M
N
0
P
Q
R
S
T
totals 
a
5/70
28/133
(11/140)
26/140 
22/133 
5/63 
30/140 
8/63 
30/140 
1 5/ 140 
13/63 
19/133 
13/112 
24/ 119 
14/112 
17/126 
13/126 
24/140 
23/126 
19/119
348/2198=15.8%
0 /1
*
(0/4)
1/2
0/1
2/3
*
0 /2
*
0/1
*1/7
0/2
0 / 1
0 /1
f*1/2
0/2
5/25=20%
0/1
1/3
(1/5)
1/4
0/5
1/3
3/7
1/4
0/5
1/8
0/4
0/6
1 /6
3/11
0/7
0/3
0/4
1/4
1/8
0/8
14/101=13.9%
0/2
1/3
(1/8 )
2/6
0/5
1/3
5/10
1/4
0/7
1/8
0/4
1/9
1/6
3/13
0/7
0/3
0/4
1/4
2/10
0/9
19/117=16.2%
this person became pregnant and was deleted from the statistics 
*lesions which began outside menses and continued into it were omitted 
t1° lesion
d when there were simultaneous lesions and positive cultures, they were counted as one
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Table 9b
The relationship of mestrual phase to lesions and/or viral shedding.
days of menstrual phase lesions in phase + cultures in phase lesions and + cultures in phase
patient total days in study total lesions total positive cultures total lesions and positive cultures
A 7/70 0/1 0/1 0/2
B 38/133 * 1/3 1/3
(15/HO) (0/4) (1/5) (1/8)
D 36/140 1/2 1/4 2/6
E 32/133 0/1 0/5 0/5
F 7/63 - 1/3 1/3
G 42/140 2/3 4/7 6/10
H 12/63 * 1/4 1/4
I 40/140 0/2 0/5 0/7
J 23/140 1/1 1/8 1/8
K 19/63 0/1 0/4 0/4
L 29/133 *3/7 2/6 5/9
M 19/112 — 1/6 1/6
N 34/119 0/2 3/11 3/13
0 22/112 0/1 1/7 1/7
P 25/126 - 0/3 0/3
Q 19/126 0/1 0/4 0/4
R 34/140 - 1/4 1/4
S 31/126 f*2/2 1/8 3/10
T 27/119 0/2 0/8 0/9
totals 496/2198=22.6% 9/26=34.6% 18/101=17.8% 26/117=22.1%
this person became pregnant and was deleted from the statistics 
*lesions which began outside menstrual phase and continued into it were omitted 
tl° lesion
d when there were simultaneous lesions and positive cultures, they were counted as one
00
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differences are not significant. Patients G and L had greater than 
50% of their lesions and/or positive cultures during the menstrual 
phase. Only participant G had 50% of positive cultures during 
"menses". (See Table 9b.)
Figure 1 illustrates the reported onset of lesions plotted in 
relation to the first day of menstrual bleeding. Because the men­
strual cycles of the women in the study ranged from 16 to 40 days the 
data were plotted + 15 days of the first day of bleeding to minimize 
possible effects of variable cycle length. Panel A illustrates onset 
of lesions for the entire study group. Because the hormonal levels 
of those women on birth control pills is different from those women 
not on birth control pills, they were removed from a portion of this 
analysis. Panel B shows the incidence of lesions of women not on the 
"pill". Although the highest incidence of reported lesion onsets 
occurred on the first day of bleeding, computer analysis for linear 
trends showed that for these test groups no day of the menstrual cycle 
was more likely to yield lesions than another. However, two indivi­
duals appeared to have lesions grouped in one portion of the menstrual 
cycle. Patient G had all three episodes of recurrent disease in the 
first 8 days of the cycle, and patient I had both episodes one week 
after the first day of bleeding or a little over 3 weeks before that 
first day of bleeding.
In the same manner, Figure 2 is demonstrative of trend for 
isolation of virus relative to menstruation. Again, computer analysis 
for linear trend indicated that no day of the cycle was more or less 
likely to yield positive cultures than another.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 1
Onset of recurrent herpes in relation to menstrual bleeding.
(Day 1 is the first day of menstrual bleeding. Negative numbers 
are days prior to the onset of bleeding. Positive numbers are days 
after the onset of bleeding.)
a. total study group
b, women on birth control pills eliminated
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 2
Effect of menstrual cycle on herpesvirus isolation.
(Day "I is the first day of menstrual bleeding. Negative numbers 
are days prior to the onset of bleeding. Positive numbers are days 
after the onset of bleeding.)
a. total study group
b. women on birth control pills eliminated
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Method of Birth Control
Birth control methods (and success) are recorded in Table 10.
Table 11 shows the effect of birth control methods on lesions and 
positive cultures. The number of women in the groups using birth con­
trol pills and lUD's were equal. To facilitate statistical analysis, 
the groups should have been of equal size. Two persons were eliminated 
from the group using other methods (none or chemical/barrier), the 
person who became pregnant and the lesbian. A three factor, one-way 
analysis of variance indicates that there is no difference in the 
groups. However, the length of the lesions appeared to.be somewhat 
longer for the group on birth control pills (x lesion length of 5.0 d 
vs. 3.0 d and 3.2 d for the other groups).
Sexual Activity
Tables 12a and b illustrate that in this study, the probability 
that sexual activity induced lesions or positive cultures was greater 
than 30% (not significant). (Patients M and P were deleted from this 
portion due to lack of response about sexual activity.) Table 13 
shows how the participants were divided to give the groups shown in 
Table 12.
Stress
For this study, stress included other illnesses, trauma, emotional 
stress, exams and excessive excerise. Patients E and M did not report 
stress, therefore they were eliminated from the stress analysis. As a 
group the remaining participants reported experiencing stress during 
14.5% of the study period. Thirty-six percent of lesions were within
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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group
Table 10
Birth control methods used during study.
patient type how long comments
1
birth
control
pill
B
D
E
J
M
S
Orthonovum
Orthonovum 
Ovcon 50
Nornal
Ovral
Orthonovum
6y
6mo
2y
8y
iy
iy
induced abortion 
(6 mo before study)
live birth 
(when off pill)
2 A 3y
lUD F 9mo induced abortion
(when on pill previously)
G 6mo
I 2y
M 3&y
P 6y
3 a C diaphragm i&y pregnant— induced abortionother (during study)
H diaphragm 3y
K diaphragm 2y had Daikon shield for 5 y
(previously)
R Encore oval Imo
b L lesbian
0 husband had vasectomy
Q sterilized tubal ligation
T not sexually active
a chemical-barrier methods 
b no birth control used
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table 11
Effect of birth control methods on recurrent herpes genitalis,
# of total days with lesions positive cultures
group
1
birth
control
pills
patient
B
D
E
J
M
S
lesions
1
2
1
1
0
3
number of recurrences
17/1
9/2
1/1
4/1
*4/2
total // of cultures
3/15
4/17
5/15
8/16
6/9
8/16
totals 8 3 5/7=5. 0 d X 34/8&38.6%
of total
2 lUD A 1 2/1 1/8
F 0 - 3/9
G 3 8/3 7/17
I 2 10/2 5/16
N 2 4/2 11/17
P 0 - 3/12
totals 8 2 4/8=3.0 d X 37/96=38.5%
of total
3 H 1 4/ 1 4/9
other K 1 2/1 4/9
R 0 - 4/16
0 1 6/1 7/14
Q 1 4/1 4/7
T 2 3/2 8/16
totals 6 19/ 6=3.2 d X 31/71=44.7%
of total
*1” lesion 26 d— omitted
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CD■DOQ.
C
gQ.
■DCD
C/)C/)
Table 12a
Effect of sexual activity on the course of recurrent herpes genitalis.
8
(O'
3.3"CD
CD■DOQ.Ca
o3"O
o
CDQ.
■DCD
C/)C/)
d with sex lesions lesions not sex followed by sex with
# days within 4d within 4d lesions in no no lesions
group patient in study after sex after sex more than 4d within 4d
1 A 47/70 1 0 1 46
active D 43/140 2 0 3 40
F 24/63 0 0 0 24
I 54/140 2 0 2 52
N 41/119 2 0 5 36
0 47/112 1 0 2 43
totals 8 0 13
2 B 20/133 1 0 3 17
moderate C 20/140 2 2 4 16
H 8/63 0 1 0 8
K 6/63 1 0 3 3
L 11/133 3 5 4 7
Q 26/112 1 0 1 25
totals 8 8 15
3 E 0/133 0 1 0 0
in­ G 2/140 1 2 1 1
active J 0/140 0 1 0 0
R 7/140 0 0 0 7
S* 4/126 3 0 2 2
T 1/119 1 1 1 0
totals 5 5 4
* sexual encounter before 1° lesion not on Table 3
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patient
Table 13 
Distribution of sexual activity 
# of wks in study x // of X/wk group
A 10 4.7 1
B 19 1.1 2
C 20 1 .0 2
D 20 2.2 1
E 19 0 3
F 9 2.7 1
G 20 0.1 3
H 9 0.9 2
I 20 2.7 1
J 20 0 3
K 9 0.7 2
L 19 0.6 2
N 17 2.4 1
0 16 2.9 1
Q 18 1.4 2
R 20 0.4 3
S 18 0.2 3
T 17 <0.1 3
x=1 .2 times/week
1 . sexually active
2. average sexual activity
below average sexual activity
3 2 1
<0.4 0.6 - 1.4 >2.2
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four days after stress and 53.5% of all positive cultures were within 
four days after stressful events. See Table 14. Friedman's multiple 
correlation coefficient analysis revealed a correlation coefficient of 
.774 between lesions and stress and .855 between positive cultures and 
stress (eitherbefore or after). These statistics were the most signi­
ficant of the study. Factor analysis suggested that stress was domin­
ant over lesions. Therefore, more lesions may have been caused by 
stress than stress caused by lesions. There is an interrelationship 
between these variables so they can not be totally separated. Stress 
contributes to lesions and lesions to stress.
Serological Data
Table 15 displays the serological data for this study. Only one 
individual had dominant type 1 or type 2 antibodies (four-fold differ­
ence in titers) more than once during the study. That participant (H) 
had dominant type 1 antibodies both times her serum was assayed even 
when virus was isolated.
The average neutralizing antibody titer for the study was approx­
imately 32 for HSV I and 32 for HSV II in the absence of lesions or 
positive viral cultures. When positive cultures were present con- 
cominantly, the average serological titers were approximately 64 for 
HSV I and 32 for HSV II. This held true even if lesions were present. 
When lesions alone were present, in the absence of positive cultures, 
the serum neutralization antibody titers were approximately 16 for 
each virus. A possible reason for this is suggested in the discussion.
Serological data is also presented in Table 4, where the highest 
value for neutralizing antibody titers for each participant is shown
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Table 14
Effect of stress on recurrent or asymptomatic herpes genitalis.
patient 9 d with stress total lesions related^
+ cultures related 
to stressreportea ii o i days lesions to stress cultures related'" 
to stress
A 7/70 1 1 (100%) 0/1
B 12/133 1 0 <0) 2/3
C 12/140 4 0 (0) 0/0
D 13/140 2 0 (0) 2/3
F 5/63 0 0 - 0/1
G 14/140 3 »2 (67) 4/6
H 2/63 1 1 ( 100) 1/1
I 21/140 2 0 (0) 0/3
J 18/140 1 0 (0) 3/3
K 16/63 1 »1 ( 100) 3/5
L 25/133 a 4 (50) 2/6
N 33/119 2 11 * (50) 6/8
0 29/112 1 0 (0) 5/9
P 1/126 0 0 - 0/1
Û 17/105 1 0 (0) 1/2
R 30/140 0 0 - 1/7
S 32/126 3 1 (33) 5/9
T 16/119 2 1 (50) 3/3
totals 303/2093
(14.5%)
33 12 (36%) 38/71
(53.5%)
^lesions occurring within 4 <i after subjectively perceived stress 
cultures occurring within 4 d after subjectively perceived stress 
^cultures taken within 4 d after subjectively perceived stress 
*exam on first day of lesion suggested as stress prior to lesion (studying)
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Table 15
Serological Data
patient SN antibody titer HSV I/HSV II
A 32/16
B 8/16*Y
C 32/16, 8/8^, 8/8
D 16/16, 16/32®
E 256/128, <2/<2®G, 128/64
<4/16, 512/256®'**
G <4/16, 8/8®
H 32/8, 16/2®^
I 16/32®, 8/2^, 4/8
J 16/128® 32/32
K 4/4, 4/2®, 4/2
L 16/2
M <8/16®, 8/8®
N 8/16^, 64/<4®
0 8/16, 32/16®
P 32/16
Q 16/64
R 16/32, 16/64
S 64/32*7, 8/2®, 8/64®
T 64/128®, 4/64, 32/16
a + isolate same day 
6 first day of lesion 
Y lesion present for >1 wk 
6 fourth day of lesion 
e only one outbreak in 1974 
t one + isolate 2 wks previously 
* 1° lesion
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along with the length of time each had been infected at the start of 
the study. The participants were divided into two groups of ten.
Those who had been infected 9 mo of less had a mean high neutralizing 
antibody titer of 30, while those who had been infected 17 mo or more 
had a mean high neutralizing antibody titer of 126. There is overlap 
between the groups, but there are also differences. Four of the people 
in the "long infection" group had neutralizing antibody titers higher 
than that found in any of the "short infectiori' group and two of the 
"short infection" group had high serum neutralizing antibody titers 
lower than any of the "long infection" group. The difference between 
the two groups in this study is highly significant (p<0.01).
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DISCUSSION
Many of the participants in this study were extremely eager to 
take part. Several of them were unaware of the permanence of herpes 
genitalis or its consequences until they read Exhibit A. The physi­
cians had not taken time to explain the details to their patients. 
Numerous persons were eager to discuss herpes genitalis with someone 
possessing a little knowledge, time and patience (even persons outside 
the study). One male eagerly volunteered to participate. When he 
was rejected, he coerced his girlfriend (R) into volunteering for the 
study. Although she never had a lesion, she was culture positive 
during the study.
The follow-up study was also accepted eagerly by the participants. 
Recent newspaper and television coverage of herpesvirus, its vast 
number of victims and research for cures had increased the interest 
of many of the people. Some unusual reactions were revealed in the 
follow-up questionnaire. One person had decided to try acupuncture 
treatments for the disease. Another woman suggested that her discon­
nection of emotion from sex might cause herpes recurrences to persist. 
Each follow-up participant had obviously thought about the problem 
extensively.
This study consisted of approximately 750 cultures (358 culture 
sets, cervical and vaginal, plus 34 lesions) and 52 antibody determina­
tions. In 1978 the charge for a herpes culture was $15 and for a serum 
neutralization assay $7-50. Thus, the total cost for the study would
have been $11,640 in 1978 dollars, if anyone had been paying for it.
64
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The high cost of this study may explain the paucity of comparable data. 
Misdiagnoses
In the group which was eliminated from the statistical analyses 
of herpes genitalis parameters, 50% probably did not have herpes 
simplex. That group represents 16.7% (1/6) of all those persons 
studied. Even if the two participants with presumptive herpes zoster 
infections were considered to have "herpes genitalis", 10% of the study 
group were still misdiagnosed. If that percentage is representative 
of the number of persons who are informed that they have genital herpes 
without actually having it, many persons are given undue fears by 
that burden. One participant (T) practically gave up sex because of 
her herpes infection. Participant S, age 18, commented that she would 
become a nun if it were not already too late for that. One person (a) 
who was eliminated from the statistics because she lacked herpesvirus 
had given up sex. She also had become extremely emotionally disturbed. 
Each of her 9 visits included lengthy discussions about the disease 
and the lack of counseling by the physician.
Another concern for misdiagnosis of herpes genitalis is elicited 
by the use of serological methods (without culture) to eliminate herpes 
as a cause of infection. Culture alone has drawbacks (to be discussed 
more extensively below). During an active recrudescence of herpes 
infection, antibodies may be depleted by neutralizing the infecting 
virus (to be discussed below). Thus, false negative results may lead 
to diagnoses such as "nonspecific vaginitis", which would be very 
misleading for patients and their doctors in the future.
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Length of Infection
No correlation was found between the length of time an individual 
had been infected with herpesvirus (0 to 64 mo at the start of the 
study) and either the number of recurrences, length of lesions or 
number of positive herpes isolates. Yet it is generally believed that 
herpes genitalis becomes less severe for the victim with time (61). 
Perhaps this study did not demonstrate a lessening of recurrent disease 
because all but 2 of the women in the group were within the peak age 
range for herpes genitalis of 20 to 29 (>50% of women with the disease 
(61)). Another alternative is that lessening is not apparent until 
after 3 y of disease have passed, and three-fourths of the women in 
the study had been infected 37 mo or less. However, the four partici­
pants who entered the study at 40 to 64 mo after their primary attack 
did not differ significantly from those who had been infected for 9 mo 
or less. In the follow-up study, while one individual (N), at 32 years 
old after 6 y of genital herpes, had been 2 y without a lesion, an­
other participant (I) at 30 years old after 7 y with genital herpes, 
had disease with greatly increased severity (from 1 to 2 recurrences 
per year to 1 every month or 2— a 6-fold increase). Individual 
deviations such as these cannot be explained; the participants them­
selves, by now well informed about genital herpes, were unable to offer 
even tentative explanations.
Viral Isolation from Lesions
Successful virus isolation directly from swabs of genital herpetic 
lesions was low in this study ( 2^) probably because few cultures 
were attempted during optimal conditions. Chang, et al. (17) reported
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an 82% rate of isolation from fluid obtained by aspiration from intact 
vesicles. No attempt was made to aspirate intact vesicles in this 
study. Of studies of recurrent oral lesion, one by lesion puncture 
yeilded an 89% isolation rate (68); and another performed in a manner 
similar to this study yielded a 24% isolation rate (23). Sumaya et al. 
(70), reported a 68.4% rate of virus isolation from lesions, but only 
cultured 8% of the lesions that they saw and did not report how the 8% 
were selected. These data suggest a cause for concern about accurate 
diagnoses of the etiological agents of lesions even by culturing. 
Clinicians are seldom presented with prime conditions for viral cultures 
because the victims, either through procrastintion until the disease 
is unbearable or through difficulty in getting an appointment, rarely 
see a physician during the first few days of lesion formation, prior 
to vesicle rupture. The reasons for failure to isolate virus from 
open lesions are not clear.
Source of Virus Shedding
Of the 161 positive cultures 3.1% (5) were from lesions, 52.2%
(84) from cervixes and 44.7% (72) from vaginal walls. Seventy-five 
percent of the positive cultures were obtained in the absence of 
lesions. Even when lesions were present, there was only a 50 % viral 
isolation rate from all sources. Those isolates were 36.4% cervical, 
410% vaginal and 22.7% from lesions. These data indicate that cer­
vical and/or vaginal cultures were superior indicators of viral presence 
even when lesions were present. Patients I and K had virus isolated 
from the cervix more often than from vaginal walls. It was noted that 
few other studies repôrted attempts to isolate virus from areas other
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than the lesion when lesions were present. Guinan, et al. (31) cul­
tured the cervix and reported a 33% viral isolation rate. No cervical 
lesions were seen in their study or this one.
According to this study, one is only 2.8 times more likely to 
isolate virus when a lesion is present than in the absence of lesions. 
Others have had much less success in isolating virus from asymptomatic 
patients. A possible explanation comes from the results of Guinan, et 
al. (31) who found virus titers much higher during lesions than asymp­
tomatic isolation (10^ vs 10* plaque-forming units).
Asymptomatic Herpes Genitalis
The epidemiological importance of asymptomatic genital shedding 
of herpes simplex virus by people known to be infected has received 
limited attention. Most studies have focused on recurrences of lesions 
or the association of herpesvirus type 2 infection with neoplasia of 
the cervix (36,44,49). Several studies of asymptomatic virus shedding 
have generally been carried out in women with no history of active 
herpes lesions. A venereal disease clinic in London found .89% asymp­
tomatic shedding (77), and a study of hospitality women in Thailand 
revealed an 8.9% rate of asymptomatic virus shedding (72). It has 
usually been assumed that people who have recurrent herpetic lesions 
are infectious only when lesions are present (16). It is also widely 
believed that only a few women shed virus asymptomatically. Other 
studies have reported 2 of 6 (60), 2 of 10 (26), 1 of 27 (31), 4 of 
49 (2), and 14 of 157 (72). Adam, et al. (2) noted that women with 
asymptomatic viral isolates were unaware of overt genital herpes
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in their recent sex partners before the viral isolations; thus the 
isolated virus probably was produced by the women themselves and not 
by their sex partners. All 20 women with herpes simplex genitalis 
who completed this study shed virus asymptomatically at least once 
during the study. And 75% of positive cultures in this study were 
obtained in the absence of lesions. Most of the isolations could not 
be a consequence of a recent sexual encounter with an infected part­
ner. The data presented in this study suggest that virus shedding 
occurs during a large portion of the lives of most victims of genital 
herpes.
In this study, unlike those reported above, the virus was not 
frozen prior to culture which may have accounted for the higher fre­
quency of virus isolation in the absence of lesions. Guinan, et al. (31) 
reported a low titer of infectious virus in their study. These data 
do not provide information about the potential infactivity of asymp­
tomatically shed virus. However, one participant (R), who has never 
(up to 1981) had a lesion, reported that she apparently infected her 
husband,
Factors that Affect Recurrent Disease 
Menstrual Cycle
Neither the menstrual bleeding nor stage in the menstrual cycle 
of persons in this study appeared to affect the course of recurrent 
or asymptomatic herpes genitalis. The study group varied so much that 
scatter resulted in no correlation for the group. However, the re­
currences of patients G and L did appear to be affect by the menstrual 
cycle (>50% of lesions or positive cultures occurred during the
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post-secretory phase). Also, patient G incurred 4 of 7 positive 
cultures during menstrual bleeding.
Rattray, et al. (60) reported that no discernable relationship 
between menstrual period and onset of recurrent genital infection was 
present. This study confirmed their finding and extended it to include 
no correlation between menses and viral isolation. And yet, Nahmias 
and Roizman (51) in a recent review indicated that the menstrual cycle, 
or at least hormones, affected recurrent disease. A biochemical study 
may be necessary to determine if hormones actually affect the disease. 
It may be that stress precipitated by the emotional chapges accompany­
ing menstruation rather than the hormone levels themselves lead to 
reactivation of virus. (This question of the effects of hormone levels 
is possibly relevant to the next two sections as well.)
Method of Birth Control
It has been suggested that birth control pills may influence the 
course of recurrent herpes genitalis (3,44,77). This study revealed 
that birth control methods (pill vs. lUD vs. other) had no influence 
on the number of recurrent lesions or viral isolations of the women.
It did appear that the pill prolonged the duration of lesions, but 
because of variation within the groups, the difference was not statis­
tically significant. Birth control methods may not influence herpes 
28,44)j the use of reliable contraceptives such as birth control 
pills or lUD's may lead to the increased sexual activity, and hence 
a greater incidence of herpes genitalis among the users of birth 
control methods.
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Sexual Activity
The amount of sexual activity of a person with recurrent herpes 
genitalis has also been postulated to affect the recurrence of the 
disease (62). This study showed no correlation between sexual acti­
vity and lesions or positive cultures (p>.30). This is in agreement 
with Rattray, et al, (60) who found no association (p>0.05) between 
the number of days since sexual activity and recurrences or viral 
isolation. The lack of correlation between sexual activity and positive 
virus cultures, as well as the presence of detectable virus in people 
with no recent sexual experiences suggests that the "asymptomatic virus 
shedding" detected in this study was actually virus shedding and not 
detection of virus transmitted by a sexual encounter.
Stress
Stresses of all types have been suggested as reactivators of 
recurrent herpes genitalis (3,51). However, since stress is largely 
subjective, adequate study of such a parameter is difficult. For 
purposes of this study, several types of stressful situations includ­
ing exams, terminations of important relationships, deaths in the 
family, excessive physical exercise and illness were grouped together 
(the previously discussed sexual activity was not included). Statis­
tical analysis of the data revealed that subjectively perceived stress 
had a significant influence on both recurrent and asymptomatic herpes 
genitalis. In fact, stress was the only variable that was found to 
substantially influence the incidence of disease or virus shedding.
In the follow-up study, the one participant (R) who herself had 
never experienced overt lesions noted that she apparently transmitted
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herpes to her husband..."during a particularly stressful month for 
me"... Four of the seven who participated in the follow-up reported 
stress as the only notable event related to their recurrences.
Another interesting finding from this portion of the study was 
that stress and herpes genitalis were statistically correlated in two 
ways: In addition to finding that stress induced herpes, it also
appeared that herpes induced stress. That herpes attacks induced stress 
seems reasonable. Contraction of or recurrence of an incurable sex­
ually transmitted disease would seem likely to cause emotional stress 
(56). It would appear that when a patient is disturbed by an unde­
sirable reminder of this, she finds other situations more stressful 
than she would if she were in a "normal" state of mind.
Serology
Except in one case, the serological data were not adequate to 
reveal whether the participants were infected by herpes simplex I or 
II, Participant H probably had HSV I because both sera had >4-fold 
higher HSV I antibodies than HSV II antibodies.
Participant K demonstrated such low antibody titers that if 
diagnosis of the disease had been by this serological method, she 
probably would have been found negative. Participant F also had very 
low serum antibody titers and had had only one lesion, a primary, 
in 1974. She exhibited asymptomatic virus shedding during this study, 
and the serum sample taken two weeks later revealed the highest anti­
body titer in the study. It is unfortunate that she was lost to 
follow-up. It would have been interesting to know whether her very 
high antibody response would have put her infection back into a
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quiescent phase and again allowed her antibody titer to drop. Parti­
cipants F and K provide warning that low titers of neutralizing antibody 
for herpes simplex do not indicate lack of infection or preclude 
recurrences.
Another type of "false negative" antibody titer is exhibited 
especially well by participant E. Wear the beginning of the study 
her antibody titers were 256 for HSV I and 128 for HSV II. In mid­
study, when her only lesion was present, neutralizing antibody titers 
dropped to undetectable levels. Later in the study the titers were 
resotred to 128 for HSV I and 64 for HSV II. This suggests that the 
neutralizing antibodies were utilized to inactivate the virus when the 
lesion occurred. This is a possible reason for the difficulty in 
isolating virus from lesions after the first days of a recurrence.
It also provides a warning for those who would use antibody titers to 
rule out the presence of herpes infections: they may be reduced during
times of active lesions or asymptomatic viral shedding. Participants 
I, N, S and T also demonstrated significant reductions in antibody titers 
when lesions were present or virus was isolated. Further, low antibody 
levels in some people do not preclude recurrences, therefore, the 
diagnostic value of low serum antibody levels, especially early after 
infection, is negligible. More rigorous study of serology with virus 
isolation is necessary to establish the virus' influence on antibodies.
Although serology has been used extensively to diagnose herpes 
cases (11,17,48,75), and has been the prime method used to correlate 
herpes simplex II with cervical carcinoma (49), the reliability of
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most methods have been questioned. Prakash and Seth reported that 
indirect hemagglutination did not differentiate between HSV I and II 
(58). Douglas, et al. (23) found no correlation between serum neu­
tralizing antibodies and viral presence for herpes labialis. In this 
study 11 out of 41 serum samples from patients with active (virus- 
producing) genital herpes simplex infections were borderline (neither 
HSV I nor HSV II titers over 8) or negative (titers 4 or less). These 
data suggest that serological methods should not be used without 
concimitant cultures. However, it should be borne in mind that nega­
tive culture data does not always mean lack of infection.
CONCLUSION
Although diagnosis of herpesvirus infections is becoming more 
common, the accuracy of those diagnoses may be in question. Herpes 
genitalis is an extremely complicated disease which may be affected 
by a large array of biological and environmental factors. Extensive 
study of individuals or even partners with recurrent herpes genitalis 
is greatly needed to help understand the disease, its gamut of compli­
cations, and its effects upon the minds and bodies of the victims of 
this wide-spread sexually transmitted disease.
SUMMARY
In all, this study of genital herpes simplex infections included 
30 women. Ten were excluded from the final analysis. Five, all of 
whom apparently had genital herpes, did not participate sufficiently 
(less than six cultures). Five others apparently did not have genital 
herpes simplex infections, a misdiagnosis rate of 16.7%.
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Twenty women with genital herpes infections were followed for 7 
to 20 weeks. The major contribution of this study is the observation 
that all twenty of these women shed virus asymptomatically. Among 
the five eliminated for insufficient participation, two shed virus in 
the absence of symptoms. Virus was isolated from asymptomatic women 
29% of the time, and from symptomatic women 50% of the time. In these 
symptomatic women, 23% of the isolations were from swabs of the lesion 
and 77% were from the cervix or vaginal walls. The amount of virus 
from each source was not determined. A second major observation was 
that some women who had recurrent herpes lesions or viral shedding 
also had such low serum antibody t.1 ters that they might have been pre­
sumed to be uninfected. In some cases the low titer persisted over a 
prolonged period. Another group of women had significangly decreased 
antibody titers only when lesions or postive cultures were present, 
as if the antibody was bound up in attempts to neutralize the virus.
A third major observation of this study is that neutralizing antibody 
titers increased with length of time since primary infection.
A number of parameters were analyzed to determine their possible 
affect upon lesions or positive cultures. Subjectively defined stress 
was the only variable which exhibited a significant positive correla­
tion to the disease. Sexual activity, method of birth control, men­
strual cycle, and length of infection did not correlate with recurrent 
lesions or positive cultures of herpes simplex genitalis.
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APPENDIX 
Media Formulations
Cell Culture Medium
m e m ......................... 9.6 g
T D W ................... . . 1 . 0 1
E C S ......................... 100 ml
NaHCO^....................... 1.0 g
L-Glutamine 0.1 g
antibiotic stock* . . . . 1.0 ml
Cell Maintenance Medium— same as Culture Medium with only 10 ml PCS
Transport Medium— same as Culture Medium with added nystatin 100 u/ml
1. Thoroughly dissolve all ingredients except NaHCO . Add NaHCO. and
dissolve. Adjust pH to 7.2 to 7-A and filter sterilize through a
2p pore-size filter.
2. Add nystatin after filtration.
3. Dispense media into sterile 100 ml, 500 ml or 1 1 containers
( 2 ml tubes for transport media).
*Antibiotic Stock (100X)
Penicillin G ..................  0.627 g
Streptomycin .................. 1.0 g
T D W ..............................10.0 ml
1. Dissolve pen-strep in TDW. Filter sterilize.
2. Dilute 1.0 ml (100X) in 1 1 of medium.
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